Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
SNDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.06 - $25.07
Previous CloseN/A
Volume201.89K
Average Volume (3M)2.12M
Market Cap
$1.18B
Enterprise Value$1.26B
Total Cash (Recent Filing)$154.08M
Total Debt (Recent Filing)$345.74M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
May 12, 2025EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.73
Shares Outstanding86,024,390
10 Day Avg. Volume1,581,249
30 Day Avg. Volume2,124,914
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)49.81
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit54.95
Enterprise Value/Ebitda-4.00
Forecast
1Y Price Target
$36.27Price Target Upside164.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Market PenetrationAccount Tiers defined by patient opportunity show high penetration into Tier I and Tier II accounts, which together represent a significant patient opportunity.
Product AdoptionSurveyed physicians and our KOL panelist anticipate rapid and broad uptake of Revuforj for r/r acute leukemia.
Regulatory ApprovalRevuforj received FDA approval for the treatment of adult and pediatric patients with relapsed or refractory acute leukemia with a KMT2A translocation.
Bears Say
Cost ConcernsR&D and SG&A expense guidance for 2025 is below pre-earnings consensus, indicating potential cost efficiency.
Market CompetitionThere is potential for a strong Revumenib launch with minimal expected rebating and a comprehensive specialty distribution network.
---
Ownership Overview
1.31% Insiders
18.04% Mutual Funds
50.59% Other Institutional Investors
16.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SNDX FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was $12.06 and its highest was $25.07 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Syndax Pharmaceuticals Inc’s market cap is $1.18B.
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is May 12, 2025 which is in 48 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on Mar 03, 2025. The company reported -$1.1 earnings per share for the quarter, missing the consensus estimate of -$0.839 by -$0.261.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -1.24.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Syndax Pharmaceuticals Inc has 86,024,390 shares outstanding.
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -$1.1 in its last earnings report, missing expectations of -$0.839. Following the earnings report the stock price went down -1.023%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in SNDX
---
Syndax Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.27 (164.17% Upside)
$36.27 (164.17% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 9.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $336.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.07%
12-Months-Change
Fundamentals
Return on Equity
-75.69%
Trailing 12-Months
Asset Growth
18.26%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
---
SNDX Company Deck
---
SNDX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Syndax has achieved significant milestones with the approval and commercial launch of two first-in-class medicines, generating initial revenues and securing a strong financial position. However, challenges remain in achieving full market penetration and managing competition. The overall sentiment reflects a positive outlook with some areas needing attention.Read More>---
SNDX Stock 12 Month Forecast
Average Price Target
$36.27
▲(164.17% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering SNDX
1 Year
1 Year Success Rate
10/18 ratings generated profit
1 Year Average Return
+25.66%
reiterated a buy rating 22 days ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +25.66% per trade.
---